TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Effects on Cue Reactivity in Response to Virtual Reality Public Speaking Environment
Brief Summary: This is a pilot study that will focus on the collection of preliminary data to determine the efficacy of quetiapine for individuals with social phobia. We hypothesize that individuals will react with less self-reported anxiety and physiological reactivity in the drug condition than in the placebo condition. If true, this would constitute a strong signal for a significant treatment effect for quetiapine in social phobia. A positive treatment effect in this study would provide rationale for further investigation of the efficacy of quetiapine for cue reactivity for individuals with social phobia. Further study would include increased sample size in order to obtain statistical power and replication of findings. We will utilize the IR formulation of quetiapine.


Options:
A: Intervention Type: DRUG; Name: LY686017; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: vestipitant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): N/A
D: Arm Label: Vilazodone; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ranibizumab for Edema of the Macula in Diabetes: a Phase 2 Study ( The Read-2 Study)
Brief Summary: This study is being done to see if the investigational drug Ranibizumab (RBZ) given by injection into the eye, is safe and effective to use in people with diabetic macular edema (DME). The investigators want to compare RBZ to laser treatment which is the current standard way to treat DME.

RBZ blocks a growth factor that is thought to be involved in the formation of abnormal blood vessels that cause loss of vision in patients with DME.


Options:
A: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.3 mg | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.5 mg | Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab 0.3 mg; Assigned to Arm(s): Ranibizumab 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab 0.5 mg; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection
B: Arm Label: Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser photocoagulation | Arm Label: Laser with Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser photocoagulation | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser with Ranibizumab, Ranibizumab | Intervention Type: PROCEDURE; Name: Laser photocoagulation; Assigned to Arm(s): Laser, Laser with Ranibizumab
C: Intervention Type: DRUG; Name: Triamcinolone, Bevacizumab; Assigned to Arm(s): N/A
D: Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.3 mg intravitreal ranibizumab | Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: 2.0 mg intravitreal aflibercept | Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: 1.25 mg intravitreal bevacizumab | Intervention Type: DRUG; Name: 2.0 mg intravitreal aflibercept; Assigned to Arm(s): Aflibercept | Intervention Type: DRUG; Name: 1.25 mg intravitreal bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: 0.3 mg intravitreal ranibizumab; Assigned to Arm(s): Ranibizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ranibizumab for Edema of the Macula in Diabetes: a Phase 2 Study ( The Read-2 Study)
Brief Summary: This study is being done to see if the investigational drug Ranibizumab (RBZ) given by injection into the eye, is safe and effective to use in people with diabetic macular edema (DME). The investigators want to compare RBZ to laser treatment which is the current standard way to treat DME.

RBZ blocks a growth factor that is thought to be involved in the formation of abnormal blood vessels that cause loss of vision in patients with DME.


Options:
A: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser
B: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser
C: Arm Label: Sham Control; Type: SHAM_COMPARATOR; Interventions: Drug: Standard of Care | Arm Label: Macugen; Type: EXPERIMENTAL; Interventions: Drug: Macugen | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Sham Control | Intervention Type: DRUG; Name: Macugen; Assigned to Arm(s): Macugen
D: Arm Label: Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser photocoagulation | Arm Label: Laser with Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser photocoagulation | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser with Ranibizumab, Ranibizumab | Intervention Type: PROCEDURE; Name: Laser photocoagulation; Assigned to Arm(s): Laser, Laser with Ranibizumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can a Novel Treatment Using "Mandometer®" Technology Improve Weight Loss in a Childhood Obesity Clinic?
Brief Summary: We run a successful clinic in Bristol for children with severe obesity who already demonstrate many features to suggest they are at increased risk of early diabetes and heart disease. However, we have found that young children respond better to simple interventions than do adolescents. We have used a new treatment regimen "Mandometer®" to help our most difficult adolescent cases lose weight. We would like to do a study to see if all adolescents might improve weight loss using this technology compared to what we routinely offer


Options:
A: Arm Label: Exercise prescription; Type: OTHER; Interventions: Behavioral: PEP intervention | Intervention Type: BEHAVIORAL; Name: PEP intervention; Assigned to Arm(s): Exercise prescription
B: Arm Label: Healthy lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy lifestyle managment | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Healthy lifestyle managment; Assigned to Arm(s): Healthy lifestyle intervention
C: Arm Label: Mandometer; Type: EXPERIMENTAL; Interventions: Device: Mandometer, Behavioral: Lifestyle | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Mandometer | Intervention Type: DEVICE; Name: Mandometer; Assigned to Arm(s): Control, Mandometer | Intervention Type: BEHAVIORAL; Name: Lifestyle; Assigned to Arm(s): Mandometer
D: Arm Label: Mot. & Fam. Weight Loss + Online Interv.; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational and Family Weight Loss, Behavioral: Online Intervention | Arm Label: Mot. & Fam. Weight Loss + Online Control; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational and Family Weight Loss, Behavioral: Online Control | Arm Label: Basic Health Educ. & Online Interv.; Type: EXPERIMENTAL; Interventions: Behavioral: Basic Health Education, Behavioral: Online Intervention | Arm Label: Basic Health Educ. & Online Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Health Education, Behavioral: Online Control | Intervention Type: BEHAVIORAL; Name: Motivational and Family Weight Loss; Assigned to Arm(s): Mot. & Fam. Weight Loss + Online Control, Mot. & Fam. Weight Loss + Online Interv. | Intervention Type: BEHAVIORAL; Name: Basic Health Education; Assigned to Arm(s): Basic Health Educ. & Online Control, Basic Health Educ. & Online Interv. | Intervention Type: BEHAVIORAL; Name: Online Intervention; Assigned to Arm(s): Basic Health Educ. & Online Interv., Mot. & Fam. Weight Loss + Online Interv. | Intervention Type: BEHAVIORAL; Name: Online Control; Assigned to Arm(s): Basic Health Educ. & Online Control, Mot. & Fam. Weight Loss + Online Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice
Brief Summary: To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.


Options:
A: Arm Label: FDC Fixed Dose Combination; Type: EXPERIMENTAL; Interventions: Drug: FDC | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Separately drugs, simvastatin, aspirin and ramipril | Intervention Type: DRUG; Name: FDC; Assigned to Arm(s): FDC Fixed Dose Combination | Intervention Type: DRUG; Name: Separately drugs, simvastatin, aspirin and ramipril; Assigned to Arm(s): Conventional treatment
B: Arm Label: Polypill; Type: EXPERIMENTAL; Interventions: Drug: Polypill | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Polypill; Assigned to Arm(s): Polypill
C: Arm Label: OM40/AML10; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil, Drug: Amlodipine | Arm Label: OM40/HCTZ25; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olmesartan medoxomil, Drug: Hydrochlorothiazide | Arm Label: AML10/HCTZ25; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, Drug: Hydrochlorothiazide | Arm Label: OM40/AML10/HCTZ25; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olmesartan medoxomil, Drug: Amlodipine, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): OM40/AML10, OM40/AML10/HCTZ25, OM40/HCTZ25 | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): AML10/HCTZ25, OM40/AML10, OM40/AML10/HCTZ25 | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): AML10/HCTZ25, OM40/AML10/HCTZ25, OM40/HCTZ25
D: Arm Label: Caduet; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine besylate/atorvastatin calcium single pill combination | Intervention Type: DRUG; Name: Amlodipine besylate/atorvastatin calcium single pill combination; Assigned to Arm(s): Caduet

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice
Brief Summary: To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.


Options:
A: Arm Label: 1, POLYCAP; Type: EXPERIMENTAL; Interventions: Drug: POLYCAP | Arm Label: 2 B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Thiazides | Arm Label: 3 C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril with Thiazide | Arm Label: 4 D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Thiazide plus atenolol | Arm Label: 5, E; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril plus atenolol | Arm Label: 6, F; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril plus atenolol plus thiazide | Arm Label: 7,G; Type: ACTIVE_COMPARATOR; Interventions: Drug: Thiazide + Ramipril+Atenolol+Aspirin | Arm Label: 8,H; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Arm Label: 9,A; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin | Intervention Type: DRUG; Name: Thiazides; Assigned to Arm(s): 2 B | Intervention Type: DRUG; Name: Ramipril with Thiazide; Assigned to Arm(s): 3 C | Intervention Type: DRUG; Name: Thiazide plus atenolol; Assigned to Arm(s): 4 D | Intervention Type: DRUG; Name: Ramipril plus atenolol; Assigned to Arm(s): 5, E | Intervention Type: DRUG; Name: Ramipril plus atenolol plus thiazide; Assigned to Arm(s): 6, F | Intervention Type: DRUG; Name: POLYCAP; Assigned to Arm(s): 1, POLYCAP | Intervention Type: DRUG; Name: Thiazide + Ramipril+Atenolol+Aspirin; Assigned to Arm(s): 7,G | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): 8,H | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): 9,A
B: Arm Label: FDC Fixed Dose Combination; Type: EXPERIMENTAL; Interventions: Drug: FDC | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Separately drugs, simvastatin, aspirin and ramipril | Intervention Type: DRUG; Name: FDC; Assigned to Arm(s): FDC Fixed Dose Combination | Intervention Type: DRUG; Name: Separately drugs, simvastatin, aspirin and ramipril; Assigned to Arm(s): Conventional treatment
C: Intervention Type: DRUG; Name: fixed-dose combination of telmisartan 40mg+amlodipine 10mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fixed-dose combination of telmisartan 80mg+amlodipine10mg; Assigned to Arm(s): N/A
D: Arm Label: Caduet; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine besylate/atorvastatin calcium single pill combination | Intervention Type: DRUG; Name: Amlodipine besylate/atorvastatin calcium single pill combination; Assigned to Arm(s): Caduet

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Study of Bevacizumab With Abraxane in Patients With Recurrent, Platinum-Resistant Primary Epithelial Ovarian or Primary Peritoneal Carcinoma
Brief Summary: The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer. The study will also evaluate how the patient's quality of life is during their treatment.


Options:
A: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly; Assigned to Arm(s): Chemotherapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Abraxane; Assigned to Arm(s): N/A
D: Arm Label: avelumab; Type: EXPERIMENTAL; Interventions: Biological: avelumab | Arm Label: avelumab plus pegylated liposomal doxorubicin (PLD); Type: EXPERIMENTAL; Interventions: Biological: avelumab, Drug: PLD | Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD | Intervention Type: BIOLOGICAL; Name: avelumab; Assigned to Arm(s): avelumab, avelumab plus pegylated liposomal doxorubicin (PLD) | Intervention Type: DRUG; Name: PLD; Assigned to Arm(s): PLD, avelumab plus pegylated liposomal doxorubicin (PLD)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Tinzaparin Sodium on Cardio-vascular OUtcomes and on Blood Lipids in Diabetic Patients on Chronic HEmodialysis: A Long-term, Prospective Study (The "Tinzaparin COULD HELP" Study).
Brief Summary: Low molecular weight heparin (LMWH) provides a safe and effective alternative to UFH for hemodialysis anticoagulation. While unfractionated (UF) heparin has been implicated in hyper-lipidemia, the effect of LMWHs on the lipid profile in non-diabetic patients on chronic hemodialysis remains controversial. The effect of LMWH in diabetic patients, a high risk group for developing hyper-lipidemia and cardio-vascular disease, has not been studied.

The study intends to examine the long-term effects of the replacement of UFH by LMWH (tinzaparin sodium) on cardio-vascular outcomes and on lipoprotein profiles in a large group of diabetic patients stable on HD.


Options:
A: Arm Label: Tinzaparin; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin administration | Arm Label: Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin administration | Intervention Type: DRUG; Name: Tinzaparin administration; Assigned to Arm(s): Tinzaparin | Intervention Type: DRUG; Name: Heparin administration; Assigned to Arm(s): Heparin
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: law molecular weigth heparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: unfractioned heparin | Intervention Type: DRUG; Name: law molecular weigth heparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: unfractioned heparin; Assigned to Arm(s): B
C: Arm Label: Apixaban 2.5 mg twice daily and standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban 2.5 milligram Oral Tablet | Arm Label: Standard of care and no anticoagulation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Apixaban 2.5 milligram Oral Tablet; Assigned to Arm(s): Apixaban 2.5 mg twice daily and standard of care
D: Arm Label: LMWH arm; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin | Arm Label: UFH arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Intervention Type: DRUG; Name: Nadroparin; Assigned to Arm(s): LMWH arm | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): UFH arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 17-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Of Pregabalin For The Treatment Of Chronic Central Neuropathic Pain After Spinal Cord Injury
Brief Summary: The purpose of this study is to evaluate if pregabalin relieves nerve pain associated with spinal cord injury compared to placebo (pill that contains no active medicine). This study will also evaluate the safety of pregabalin in this patient population.


Options:
A: Arm Label: HF10 therapy plus CMM; Type: ACTIVE_COMPARATOR; Interventions: Device: Senza HF10 Therapy | Arm Label: CMM Alone; Type: OTHER; Interventions: Other: CMM | Intervention Type: DEVICE; Name: Senza HF10 Therapy; Assigned to Arm(s): HF10 therapy plus CMM | Intervention Type: OTHER; Name: CMM; Assigned to Arm(s): CMM Alone
B: Arm Label: matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): matched placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pregabalin 300 mg/day; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: Pregabalin 600 mg/day; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin 300 mg/day | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin 600 mg/day
D: Arm Label: lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: lenalidomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): lenalidomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B